Biotech Values

[Mufaso]

KeyBioscience has a DACRA or "dual amylin calcitonin receptor agonist" that they have partnered with LLY. (In the post I'm replying to, I should have noted that VKTX's amylin analogue is actually a DACRA and hits both amylin and calcitonin receptors.)

KeyBioscience Announces Extension of Strategic Collaboration with Lilly

https://www.newswire.ca/news-releases/keybioscience-announces-extension-of-strategic-collaboration-with-lilly-854642176.html

LUGANO, Switzerland, Oct. 10, 2024 /CNW/ -- KeyBioscience and Eli Lilly and Company have agreed to extend their collaboration on the development of Dual Amylin Calcitonin Receptor Agonists (DACRA), a new class of potential treatments for obesity and related disorders.

This collaboration extends Lilly's rights to KeyBioscience's DACRA platform, including a new molecule that is anticipated to enter a Phase 2 study in people with obesity and osteoarthritis (OA) later this year. KeyBioscience will conduct and complete this study which is planning to enroll 600 people and have dual primary endpoints on body weight and alleviation of OA pain.

"DACRAs have been shown to be potent weight loss agents with potential for additional insulin sensitization. We are extremely excited to move forward with the clinical program, as this class in other Phase 2 trials has shown significant weight loss in people with obesity and clinically meaningful improvement of glycaemic control," said Morten Karsdal, CEO of the parent company of KeyBioscience. "We believe this is a very competitive molecule with very high potency and low immunogenicity risk and look forward to collaborating further with Lilly to advance this important work."